FOCUS ISSUE: ATRIAL FIBRILLATION: STATE-OF-THE-ART PAPER
Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation
Brett Burstein, BSc and
Stanley Nattel, MD*
Research Center and Department of Medicine, Montreal Heart Institute and Université de Montréal, and Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Manuscript received June 21, 2007;
revised manuscript received August 16, 2007,
accepted September 7, 2007.
* Reprint requests and correspondence: Dr. Stanley Nattel, 5000 Belanger Street East, Montreal H1T 1C8, Quebec, Canada. (Email: stanley.nattel{at}icm-mhi.org).
Atrial fibrillation (AF) is the most common arrhythmia in the clinical setting, and traditional pharmacological approaches have proved to have important weaknesses. Structural remodeling has been observed in both clinical and experimental AF paradigms, and is an important feature of the AF substrate, producing fibrosis that alters atrial tissue composition and function. The precise mechanisms underlying atrial fibrosis are not fully elucidated, but recent experimental studies and clinical investigations have provided valuable insights. A variety of signaling systems, particularly involving angiotensin II and related mediators, seem to be centrally involved in the promotion of fibrosis. This paper reviews the current understanding of how atrial fibrosis creates a substrate for AF, summarizes what is known about the mechanisms underlying fibrosis and its progression, and highlights emerging therapeutic approaches aimed at attenuating structural remodeling to prevent AF.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | AF = atrial fibrillation | | AngII = angiotensin II | | AT1 = angiotensin II type 1 | | CHF = congestive heart failure | | ECM = extracellular matrix | | PDGF = platelet-derived growth factor | | TGF = transforming growth factor | | VTP = ventricular tachypacing |
|
This article has been cited by other articles:

|
 |

|
 |
 
E. Anter and D. J. Callans
Pharmacological and Electrical Conversion of Atrial Fibrillation to Sinus Rhythm Is Worth the Effort
Circulation,
October 6, 2009;
120(14):
1436 - 1443.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. K. Mason and J. P. DiMarco
New Pharmacological Agents for Arrhythmias
Circ Arrhythm Electrophysiol,
October 1, 2009;
2(5):
588 - 597.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Maleckar, J. L. Greenstein, W. R. Giles, and N. A. Trayanova
K+ current changes account for the rate dependence of the action potential in the human atrial myocyte
Am J Physiol Heart Circ Physiol,
October 1, 2009;
297(4):
H1398 - H1410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Wilber
Pursuing sinus rhythm in patients with persistent atrial fibrillation: when is it too late?
J. Am. Coll. Cardiol.,
August 25, 2009;
54(9):
796 - 798.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Caso, R. Ancona, G. Di Salvo, S. Comenale Pinto, M. Macrino, V. Di Palma, A. D'Andrea, A.R. Martiniello, S. Severino, and R. Calabro
Atrial reservoir function by strain rate imaging in asymptomatic mitral stenosis: prognostic value at 3 year follow-up
Eur J Echocardiogr,
August 1, 2009;
10(6):
753 - 759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Xie, A. Garfinkel, J. N. Weiss, and Z. Qu
Cardiac alternans induced by fibroblast-myocyte coupling: mechanistic insights from computational models
Am J Physiol Heart Circ Physiol,
August 1, 2009;
297(2):
H775 - H784.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Anter, M. Jessup, and D. J. Callans
Atrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic
Circulation,
May 12, 2009;
119(18):
2516 - 2525.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Benjamin, P.-S. Chen, D. E. Bild, A. M. Mascette, C. M. Albert, A. Alonso, H. Calkins, S. J. Connolly, A. B. Curtis, D. Darbar, et al.
Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop
Circulation,
February 3, 2009;
119(4):
606 - 618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Yang, Y. Lu, and Z. Wang
Control of cardiac excitability by microRNAs
Cardiovasc Res,
September 1, 2008;
79(4):
571 - 580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Nattel, B. Burstein, and D. Dobrev
Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Circ Arrhythm Electrophysiol,
April 1, 2008;
1(1):
62 - 73.
[Full Text]
[PDF]
|
 |
|
|